Roth Capital Comments on Enovis’ Q1 Earnings (NYSE:ENOV)

Enovis Co. (NYSE:ENOV) – Equities research analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for Enovis in a report issued on Thursday, February 27th. Roth Capital analyst J. Wittes forecasts that the company will post earnings per share of $0.73 for the quarter. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.88 EPS.

Separately, Needham & Company LLC cut their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, February 27th.

Enovis Price Performance

NYSE ENOV opened at $37.83 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis has a 12 month low of $37.60 and a 12 month high of $63.96. The company’s 50 day moving average is $44.72 and its two-hundred day moving average is $44.28. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -17.27 and a beta of 1.94.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million.

Institutional Trading of Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the 4th quarter valued at about $29,000. Quadrant Capital Group LLC lifted its holdings in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. raised its stake in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the period. Finally, Quarry LP lifted its stake in Enovis by 506.1% during the fourth quarter. Quarry LP now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 749 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.